~~<i id='292031C6E8'><strike id='292031C6E8'><tt id='292031C6E8'><pre id='292031C6E8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：fashion 2025-09-30 16:28:24 - browse：9279

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

knowledge

focus

knowledge

hotspot

explore

focus

7:36JonHuntsmanlistenstoquestionsduringahearingaboutvotingrightsintheDistrictofColumbiabeforetheCons

WSS

CVS is on a mission to consolidate health care. Will it work?

Update the Apgar Score to remove skin color

High breast density mammograms need follow

Printout prescription drug information shouldn’t go digital

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

focus

explore

knowledge

How to save PrEP access — and even expand it

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

In Memoriam: Notable people who died in 2023

Update the Apgar Score to remove skin color

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Inaction leaves children at risk from dangerous chemotherapy drug

Trump demands the U.S. pay no more for drugs than other countries … again

Involuntary treatment for addiction doesn't work

Hollywood unions extend contract negotiations for actors

Does aspartame cause cancer? What new WHO guidance says

focus

Microsoft launches AI tool for clinical documentation through Epic

Can CDC director Mandy Cohen drive consensus in Washington?

Blood tests recalled over risk of missed heart attack diagnosis

Europe sees delivery challenges ahead on Alzheimer's therapies

Medicare drug price lawsuits could be good politics for Biden

Can CDC director Mandy Cohen drive consensus in Washington?

knowledge

hotspot

explore

focus